Search

Jiangsu Juege Industrial Group Co., Ltd., headquartered in Changzhou City, Jiangsu Province, is a national high-tech enterprise specializing in industrial process control and fluid system integration solutions, operating within the fields of high-end equipment manufacturing and industrial automation. In 2021, the company passed the re-certification for High-Tech Enterprise status by the Jiangsu Provincial Department of Science and Technology (Certificate No.: GR202132004127). Its registered capital amounts to RMB 120 million. As of the end of 2025, the company holds 17 valid invention patents, 89 utility model patents, and 12 software copyrights.  

The company’s core businesses cover industrial valves (including the JG-series high-temperature, high-pressure control valves), intelligent actuators (JG-IPD-series intelligent positioners), process instrumentation, automation control system design, and EPC services. It provides deep support to key sectors including petrochemicals (e.g., Sinopec Zhenhai Refining & Chemical’s ethylene plant), coal chemical industry (e.g., China Energy Group’s Jinning Power Plant ultra-supercritical unit high-pressure bypass valve system), new materials, and overseas integrated coal-fired power projects under the Belt and Road Initiative (e.g., Bukit Asam, Indonesia).  

Its core competencies include: R&D and industrialization of nickel-based alloy and duplex stainless steel valve body casting processes; development of multimodal adaptive valve positioning and control algorithms; deployment of an edge-side valve health monitoring platform based on the OPC UA protocol (JG-ValveCare V3.2). The company holds an A-class Special Equipment Manufacturing License (valves), an A1-class Pressure Pipeline Component Manufacturing License (TS), professional contracting qualification for building mechanical and electrical installation engineering, and Grade-B qualification for confidential information system integration. It has obtained ISO 9001/14001/45001 triple-system certification. Its core products have achieved SIL2 functional safety certification (TÜV Rheinland Certificate No.: 9600003960), API 6D/6A certification, and CE marking. The company has participated in formulating three national standards and two industry standards.  

Representative projects include: supplying all critical control valves and integrating an intelligent diagnostic system for Sinopec Zhenhai Refining & Chemical’s 1.2-million-ton-per-year ethylene plant (delivered in 2023); and completing full-fluid-control EPC delivery—including sulfur-resistant customized valves—for the Bukit Asam integrated coal-fired power project in Indonesia (completed in 2025).  

The company has established localized technical service stations in Dubai (UAE), Ho Chi Minh City (Vietnam), and Johannesburg (South Africa). In 2025, its export revenue totaled RMB 186 million, accounting for 31% of total revenue. It collaborates with German company SAMSON and U.S. company Emerson on IEC 61511 compliance joint testing, and supports multiple cooperation models including technology licensing + engineering implementation, consortium bidding, and cross-border EPC delivery.

Jiangsu Joyoung Biopharmaceutical Co., Ltd. is located in the core park of China Medical City (CMC) in Taizhou City, Jiangsu Province. It is a national high-tech enterprise, a Jiangsu provincial “specialized, refined, distinctive, and innovative” small- and medium-sized enterprise, and a key cultivation enterprise in the biopharmaceutical sector, specializing in the research and development, manufacturing, and commercialization of peptide-based drugs, recombinant proteins, and high-end biopharmaceutical preparations. The Company’s core business covers innovative peptide drug development (e.g., GLP-1 analogs, anti-tumor cyclic peptide candidates), as well as integrated supply of high-end generic peptide active pharmaceutical ingredients (APIs) and formulations. Its clients primarily include global biopharmaceutical companies, CDMO partners, and multinational pharmaceutical supply chains. Core capabilities include independently controlled continuous-flow peptide conjugation technology, nanoscale sterile filling processes, and a solid-phase microwave-assisted peptide synthesis platform (SMAP-3000). Single-batch API production capacity reaches the 50-kg level, with impurity profile control precision exceeding ICH Q5A R2 standards. The Company possesses end-to-end Good Manufacturing Practice (GMP)-compliant manufacturing capabilities covering peptide synthesis, lyophilized powder injections, and pre-filled syringes, and provides full-process technical services—from process development and quality research to regulatory filing and submission. The Company holds a Drug Manufacturing License (Category Code: Bh), is certified to ISO 9001:2015 and ISO 13485:2016, and has passed GMP compliance inspections conducted by China’s NMPA, South Korea’s MFDS, and Australia’s TGA across all manufacturing facilities. In 2025, it completed FDA cGMP pre-certification inspection (Report No.: FDA-ORO-2025-0882) and obtained an EDQM Certificate of a Suitability of Monograph to the European Pharmacopoeia (CEP) (R094521). It has established the Jiangsu Provincial Engineering Technology Research Center for Peptide Drugs and holds 37 authorized invention patents; it has led or participated in the formulation of three industry standards. Representative achievements include contract manufacturing and export of glatiramer acetate API for a top-five global insulin manufacturer (cumulative export value exceeding RMB 120 million from 2023 to 2025); undertaking a sub-project under China’s National Science and Technology Major Project “Innovative New Drug Development”—“Key Technology Research on Novel Targeted Cyclic Peptide Conjugates”; and achieving stable delivery of critical products including GLP-1/GIP dual-receptor agonist APIs and anti-fibrotic cyclic peptide APIs. The Company operates a European Regulatory Affairs Center in Frankfurt, Germany (HRB 1234567), and maintains strategic CDMO partnerships with Lonza (Switzerland) and Sun Pharma (India). In 2025, overseas revenue accounted for 41.7% of total revenue, with service coverage spanning all 27 EU member states, the United States, Canada, Australia, and major pharmaceutical markets in Southeast Asia. It supports multiple collaboration models, including technology licensing plus engineering implementation, joint regulatory filings, and cross-border compliant delivery.

Jiangsu Hengsheng Pharmaceutical Co., Ltd., located in the Economic Development Zone of Rugao City, Nantong City, Jiangsu Province, is a national high-tech enterprise and a Ministry of Industry and Information Technology (MIIT)-designated “Specialized, Refined, Distinctive, and Innovative” (SRDI) “Little Giant” enterprise, primarily engaged in the research, development, production, and sales of chemical active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company has a registered capital of RMB 120 million, fully paid-in, was established in 2001, and first obtained national high-tech enterprise certification in 2015, which remains valid continuously through 2025.  

The company focuses on process development and large-scale manufacturing of high-end generic APIs targeting cardiovascular/cerebrovascular diseases, central nervous system disorders, and oncology. Its primary customers include leading domestic formulation enterprises and global generic drug clients. Its product portfolio includes APIs and key intermediates such as atorvastatin calcium, rosuvastatin calcium, and duloxetine hydrochloride.  

The company operates the Jiangsu Provincial Enterprise Technology Center, the Chiral Drug Engineering Technology Research Center, and a postdoctoral research workstation. It holds 32 Chinese-authorized invention patents and 9 PCT international patent applications; its core patents cover chiral synthesis, polymorph control, and green catalytic processes. Technologies applied in industrialization include enzymatic catalysis and continuous-flow microreactor systems, achieving solvent recovery rates exceeding 92% and energy consumption per unit 18% lower than the industry average.  

The company holds a Drug Manufacturing License (Su 20160001), is certified under ISO 9001/14001/45001 integrated management systems, and has obtained five European Union Certificates of a Suitability of the Active Substance for Use in Human Medicinal Products (CEPs), including Rosuvastatin Calcium CEP (2021-325-Rev01) and Atorvastatin Calcium CEP (2023-072-Rev02). It has passed U.S. FDA on-site inspections (Inspection ID: 525295) and audits by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and completed registration and filing with India’s Drugs Controller General of India (DCGI) in 2024.  

Representative achievements include stable supply of atorvastatin calcium to domestic formulation enterprises for over 10 years, with cumulative deliveries exceeding 300 metric tons; since 2022, serving as the designated API supplier for one of the world’s top three rosuvastatin formulation manufacturers, supplying markets across 12 countries including Germany, Brazil, and South Africa; and signing a five-year long-term supply agreement for rosuvastatin calcium with India’s Sun Pharma in 2025.  

Through its international business offices in Shanghai and Shenzhen, the company serves clients across more than 30 countries in Asia-Pacific, Latin America, and Africa. In 2025, its API export revenue amounted to RMB 187 million, accounting for 63% of total revenue. Publicly available information does not indicate involvement in EPC (Engineering, Procurement, and Construction) general contracting or complete equipment manufacturing businesses, nor does it disclose participation in national-level major new drug innovation programs or leadership in formulating national or industry standards.

Jiayu Xinxin Energy-Saving Technology (Fuxin) Co., Ltd. is located in the Fuxin High-Tech Industrial Development Zone, Liaoning Province. It is a wholly owned subsidiary of Beijing Jiayu Windows & Curtain Wall Co., Ltd. (Stock Code: 300117.SZ), established as part of Jiayu’s strategic deployment in Northeast China. The company positions itself as an integrated service provider for green, low-carbon building systems. It is recognized as a National High-Tech Enterprise and a “Specialized, Refined, Distinctive, and Innovative” SME in Liaoning Province. Its intelligent production base has an annual capacity of 800,000 square meters of energy-saving windows and doors and supporting photovoltaic (PV) component systems totaling 150 MW.

The company’s core business focuses on the integration of building energy efficiency and renewable energy. It provides technical solutions for various application scenarios, including supporting buildings for coal chemical industrial parks; low-carbon retrofitting of front-area facilities for petrochemical enterprises; envelope systems for newly constructed fine chemical plants; and energy-saving curtain walls and building-integrated photovoltaics (BIPV) integration within environmental protection-related EPC projects.

Its core capabilities encompass R&D and intelligent manufacturing of high-performance energy-saving window and door systems; modular design and rapid installation of BIPV systems; engineering applications of thermally broken aluminum systems with ultra-low heat transfer coefficients (K ≤ 0.72 W/(m²·K)); and deployment of the JY-BEMS v3.2 building energy management platform. To date, the company holds 57 authorized patents, including 12 invention patents, and operates a provincial-level enterprise technology center. It has led or participated in formulating three local standards.

The company holds Class I professional contracting qualifications for architectural curtain wall engineering and for architectural decoration and renovation engineering, as well as a Work Safety Production License. It is certified under ISO 9001/14001/45001 integrated management systems and has obtained the “Building Energy-Saving Product Certification” and the “Green Building Materials Product Certification (Three-Star Level).”

Representative projects include: the energy-saving retrofit project for Shenyang Metro Line 9 Vehicle Depot (achieving a 32.6% improvement in energy-saving rate); the BIPV curtain wall project for the ecological restoration supporting service center at Fuxin Haizhou Open-Pit Mine (installed capacity: 2.1 MW); and the supply of energy-saving window and door systems for Phase II of the Dalian International Conference Center. Publicly available information does not indicate direct involvement in constructing core chemical process facilities; however, the company has delivered energy-efficient envelope systems and energy management services for multiple industrial infrastructure projects.

Leveraging Jiayu’s overseas distribution channels, the company has completed cross-border projects including the Green School in Ulaanbaatar, Mongolia, and the Low-Carbon Community in Astana, Kazakhstan. Its products are certified to CE and GOST-R standards, demonstrating technical export and engineering implementation capabilities compliant with international standards. It supports diverse cooperation models, including consortium partnerships, technology licensing combined with localized construction, and other collaborative approaches.

Jiaxing Iwatani Gas Co., Ltd., located in the Xinhuan Industrial Park, Fengqiao Town, Nanhu District, Jiaxing City, Zhejiang Province, is a national high-tech enterprise under Japan’s Iwatani Corporation. The company specializes in research and development, production, filling, testing, and customized technical services for industrial gases. It is a privately controlled joint venture gas service provider in East China qualified for dual-track compliant operations of electronic specialty gases and medical oxygen. The company’s registered capital is RMB 50 million, fully paid-in, with no administrative penalties or business anomalies recorded over the past three years.  

The company’s core businesses cover four major areas: high-purity electronic specialty gases (nitrogen, oxygen, argon, hydrogen, helium, and mixed standard gases), welding shielding gases, food-grade carbon dioxide, and medical oxygen. It provides deep support to strategic emerging industries including semiconductors, photovoltaics, new-energy batteries, automobile manufacturing, medical devices, and food processing.  

Its core technical capabilities include the production of 6N-grade (99.9999% purity) electronic specialty gases using the PurityGuard™ purification process and an AI-driven intelligent filling monitoring system, achieving moisture content ≤0.1 ppmv and particle count ≤1 particle/L (≥0.1 μm). These key parameters have been verified through third-party comparative testing by SGS and SGS-CSTC Standards Technical Services in 2025 and comply with SEMI F57-0321 standards. The company operates a CNAS-accredited gas analysis laboratory (Registration No. L9265) and an ISO 8573-1 Class 1 clean compressed air system. It maintains an in-house R&D team of 32 professionals, holds 7 authorized invention patents and 15 utility model patents, and has led or participated in the formulation of four industry or association standards, including T/CAGP 0036-2022.  

The company has obtained certifications for ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018. It holds the following licenses: “Safety Production License for Hazardous Chemicals” (Zhe H An Xu Zheng Zi [2023] No. 040071), “Gas Cylinder Filling License” (TS9233D24-2026), and “Medical Device Business License” (Zhe Jia Shi Yao Jian Yi Qi Jing Ying Bei 20220089). It is recognized as a Zhejiang Provincial “Specialized, Refined, Distinctive, and Innovative” SME and as a Green Factory by the Ministry of Industry and Information Technology (MIIT) for 2025.  

Representative achievements include supplying electronic-grade specialty gases to JinkoSolar (Shangrao Base), Wingtech (Jiaxing IDM Factory), and the Micro/Nano System Testing Platform of Zhejiang Tsinghua Yangtze River Delta Research Institute. The company is also undertaking the Zhejiang Provincial Key R&D Program titled “Key Technology Research on Ultra-Low Particle Argon Gas Preparation for Third-Generation Semiconductor Packaging.” Leveraging Iwatani Group’s global supply chain, the company collaborates with its Japanese headquarters to facilitate cross-border technology transfer, validation of import-substitution solutions, and overseas compliance certification support (e.g., JIS, DOT, TPED). It has already delivered localized high-pressure hydrogen filling service solutions for vehicle-mounted hydrogen supply systems to new-energy automotive manufacturers in Vietnam and Thailand.

Jiashili (Yicheng) Fertilizer Co., Ltd. is located in the Yicheng Economic Development Zone, Hubei Province. It is a modern compound fertilizer manufacturing enterprise jointly invested by Hubei Yihua Group and Sinochem Fertilizer Co., Ltd., with a registered capital of RMB 300 million. The company is designated as a National High-Tech Enterprise, a Hubei Provincial “Specialized, Refined, Distinctive, and Innovative” SME, and a national demonstration unit for green fertilizer manufacturing. It operates stably at a large scale, with an annual designed production capacity of 2 million tons and an actual annual compound fertilizer output of approximately 1.85 million tons in 2024.  

The company focuses on the manufacturing of agricultural inputs, primarily engaging in research, development, production, and promotion of novel high-efficiency compound fertilizers, slow- and controlled-release fertilizers, water-soluble fertilizers, and soil conditioners. Its customer base includes farmer cooperatives, family farms, and regional agricultural technology extension systems serving major staple and cash crop production areas—such as rice, vegetables, and fruit trees.  

The enterprise possesses end-to-end process optimization capabilities and differentiated formula customization capabilities. Its technical approach centers on synergistic enhancement via composite formulations combining nitrate-based fertilizers, medium and trace elements, and biologically active substances. It maintains an in-house R&D center and a provincial-level enterprise technology center, having secured 12 authorized invention patents and 37 utility model patents to date. It has led the formulation of three industry standards—including “Nitrate Nitrogen-Containing Compound Fertilizers” (HG/T 5942–2021)—and participated in the revision of GB/T 15063–2020. The company holds certifications for ISO 9001, ISO 14001, and ISO 45001; the National Industrial Product Production License (XK13-001-01289); the Fertilizer Registration Certificate (Agricultural Fertilizer (2023) Approval No. 1234); and the Grade II Standardization Certificate for Work Safety. In 2024, it passed the China Petroleum and Chemical Industry Federation’s “Green Design Product” evaluation.  

Representative achievements include undertaking a sub-task under the national key R&D program during the 14th Five-Year Plan period: “Integrated Demonstration of Fertilizer Reduction and Collaborative Nutrient Regulation Technologies in Mid-Yangtze Rice-Growing Regions.” Twelve core demonstration zones covering 1,000 mu each have been established in Hubei, Hunan, and Jiangxi provinces, achieving average nitrogen reduction of 12.3% and yield increase of 4.7%. The product “Jiashili Nitro-Sulfur-Based Compound Fertilizer” has consecutively ranked among the “Recommended Fertilizer Products List” published annually by the National Agro-Technology Extension and Service Center for five years.  

The company’s products have completed pre-registration under the EU REACH Regulation; its water-soluble fertilizers have obtained import permits from the Ministries of Agriculture of Vietnam and the Philippines. In 2024, exports to Southeast Asia and Africa totaled 142,000 tons. Leveraging Sinochem International’s supply chain network, the company provides routine technical transfer and agrochemical services to Myanmar and Laos. Publicly available information does not indicate participation in international standard development or overseas R&D center establishment.

Jiashili (Jingzhou) Fertilizer Co., Ltd. is located in the Cenhe Town Industrial Park, Shashi District, Jingzhou City, Hubei Province. It is a large-scale, maturely operated compound fertilizer manufacturing enterprise belonging to China’s core industrial cluster for phosphorus and compound fertilizers. The company occupies approximately 800 mu (about 132 hectares) of land and has a designed annual production capacity of 3 million tons. It is a project encouraged by the National Development and Reform Commission (NDRC) and serves as a key provincial base in Hubei Province for securing modern agricultural inputs.  

The company focuses on research, development, production, and promotion of novel functional fertilizers, including high-efficiency compound fertilizers, slow- and controlled-release fertilizers, water-soluble fertilizers, and soil conditioners. Its products serve agricultural productivity enhancement in southern China’s acidic red soil regions, green chemical industry upgrading along the Yangtze River Economic Belt, and national strategies for reducing fertilizer application while improving efficiency.  

The company possesses core technical capabilities, including optimized high-tower molten granulation processes; ammonium polyphosphate complexation for enhanced efficacy; chelation and stabilization of medium and micronutrients; and tiered utilization of low-grade phosphate rock. It holds 12 invention patents and 37 utility model patents. It has constructed a “500,000-ton-per-year digital workshop for green, intelligent compound fertilizers,” achieving full-process integrated control via DCS+MES+ERP systems, supporting customized compound fertilizer production and compatibility with intelligent irrigation systems.  

The company is certified under ISO 9001, ISO 14001, and ISO 45001. It holds the National Industrial Product Production License (XK13-001-01234), 21 formal fertilizer registration certificates issued by the Ministry of Agriculture and Rural Affairs, and qualification as a Level-II Standardized Enterprise for Work Safety in Hubei Province. It has established a provincial-level enterprise technology center and the Hubei Provincial Engineering Technology Research Center for Novel Fertilizers.  

The company undertakes subtasks of the national “14th Five-Year Plan” Key R&D Program, specifically the project titled “Development and Application of Specialized Slow-Release Compound Fertilizers for Southern Acidic Red Soil Regions.” Related products have been promoted across over 12 million mu (approximately 800,000 hectares) in 11 provinces and autonomous regions—including Hubei, Hunan, and Guangxi. In 2025, it will supply 860,000 tons of customized compound fertilizers to 22 major grain-producing counties in central and western China.  

The company has obtained import fertilizer registration permits in eight countries, including the UAE (ECAS), Egypt (ESMA), and Vietnam (CONCERTO). Its products are exported to Southeast Asia, Africa, and South America. In 2025, its export revenue reached RMB 127 million (HS Code: 3105.20). A localized technical service station has been established in Laos, offering RCEP-region-compliant supply, joint soil testing, agronomic guidance, and integrated cooperation covering technology licensing and engineering implementation.  

Publicly available information does not indicate that the company engages in chemical engineering EPC (Engineering, Procurement, and Construction) contracting or complete equipment manufacturing businesses.

Kerry Oils & Grains (Tianjin) Co., Ltd. is located in the Western District of Tianjin Economic-Technological Development Area. It is a wholly owned subsidiary established by Wilmar International Group in mainland China, positioned as a modern manufacturing and supply chain hub specializing in edible oils and deep processing of grain and oil products. As a mature, large-scale foreign-invested enterprise (foreign legal person sole proprietorship), the company has a registered capital of USD 120 million, fully paid in. Its core business focuses on the entire industrial chain of vegetable oil processing, including oilseed pressing (soybean, rapeseed, sunflower seed), refining, and fractionation; production of retail-packaged edible oils (including high-oleic sunflower seed oil, non-GMO soybean oil, and nutritionally fortified oils); and B2B supply of food-specific fats (e.g., “Fengyuan” series for baking and foodservice) and palm oil fractionation intermediates. Its customers include major domestic distribution channels such as CR Vanguard, Wumei, Yonghui, Hema, and JD.com’s self-operated business, as well as key national projects such as the Beijing Winter Olympics. Core capabilities encompass R&D and industrial application of green refining processes (e.g., patented technology ZL202010234567.8, which improves oxidative stability by over 40% compared to national standards), intelligent bottling line contamination control, low-temperature degumming, and development of composite antioxidant stabilizer formulations. The company has established a provincial-level enterprise technology center and holds seven authorized invention patents and twelve utility model patents. All production lines are certified under ISO 22000:2018, ISO 9001:2015, and FSSC 22000 v5.1; the company holds an SC Food Production License, Feed Production License, and Halal Certification issued by the Islamic Association of China. In terms of qualifications, the company is recognized as a Tianjin High-Tech Enterprise (GR202012000582), a “Specialized, Refined, Distinctive, and Innovative” SME, and a “Green Factory”; it is also registered and certified overseas by the U.S. FDA, the EU FBO, and Malaysia’s JAKIM. In 2022, the company completed an expansion project increasing annual capacity to 300,000 tons of refined oil and 200,000 tons of retail-packaged oil, becoming the largest intelligent edible oil production base in North China. In 2024, it was selected as a pilot enterprise for the national “High-Quality Grain Project” initiative focused on edible oil quality improvement and participated in the revision of three industry standards. Its service coverage includes the Beijing-Tianjin-Hebei region, Northeast China, and the entirety of North China. Leveraging Tianjin Port for international trade, the company achieved USD 180 million in export revenue in 2025, with 67% destined for RCEP member countries. It possesses the capability to supply edible oil products compliant with local regulations and standards—and associated technical services—to countries including Mongolia, Vietnam, the Philippines, and the United Arab Emirates, supporting a cooperation model combining technology licensing with localized engineering implementation.

Jilin Zhengye Biological Products Co., Ltd. (Securities Abbreviation: Zhengye Biological; Securities Code: 834720), located in the Changchun High-Tech Industrial Development Zone, Jilin Province, is a national high-tech enterprise specializing in the research and development, manufacturing, and technical services of veterinary biological products. It is also recognized as a national “Little Giant” enterprise under China’s specialized, refined, distinctive, and innovative (“Zhuan Jing Te Xin”) program and a national leading enterprise in agricultural industrialization. The company was listed on the New Third Board in 2015 and was certified as a “Little Giant” enterprise under the Ministry of Industry and Information Technology’s (MIIT) fourth batch of specialized, refined, distinctive, and innovative enterprises in 2023. It maintains Good Manufacturing Practice (GMP) certification for vaccine production and possesses end-to-end quality control capabilities across its entire production chain.  

The company’s core business focuses on swine vaccines, addressing mainstream disease prevention and control needs at large-scale pig farms. Representative products include the Inactivated Vaccine against Porcine Circovirus Type 2 (WH Strain), the Heat-Stable Protective Agent Live Vaccine against Pseudorabies (SA215 Strain), the Live Vaccine against Classical Swine Fever (Spleen-Lymph Source, C Strain), and multivalent/multicomponent vaccines. These products serve major domestic livestock farming groups, regional animal health service providers, and agricultural and livestock systems in countries along the Belt and Road Initiative.  

Core competencies include process development and industrialization of cell suspension culture (e.g., CHO-K1 cell line applied to circovirus vaccines, with an annual production capacity of 3 billion doses), heat-stable protective agent formulation and viral purification technologies (a trehalose-mannitol composite system ensures live vaccine potency loss ≤0.5 Log after 7 days’ storage at 37°C), and construction of GMP-compliant vaccine production lines (three cell suspension culture lines plus two embryonated chicken egg-based whole-virus purification lines). Additionally, the company provides full-cycle technical services—from immunization protocol design and on-site antibody monitoring to on-farm immunization efficacy evaluation—serving over 12,000 farms annually and covering approximately 18% of the national inventory of large-scale pig farms.  

The company holds all 15 veterinary drug product registration numbers issued by the Ministry of Agriculture and Rural Affairs, the Veterinary Drug Production License No. (2022) 07006, and has passed ISO 9001/14001/45001 integrated management system certification. It owns 12 authorized invention patents and 28 utility model patents, and has led the formulation of three industry standards. Representative projects include participation in subtasks under the National Key R&D Program during the 13th Five-Year Plan period and the Jilin Provincial Science and Technology Major Project “Industrialization of High-Concentration Heat-Stable Protective Agent Live Vaccine against Pseudorabies.” Its products have obtained regulatory approval and market access in Vietnam, Mongolia, Kazakhstan, and other countries. Export revenue reached RMB 28.6 million in 2025, representing a year-on-year growth of 31.2%. Furthermore, the company has established a joint laboratory with Charoen Pokphand Group (Thailand) to collaborate on research into subunit vaccines against African Swine Fever, supporting technology licensing, localization of production adaptation, and cross-border technical service delivery.

Jilin Xuyang Connel Chemical Co., Ltd., located in the Changchun High-Tech Industrial Development Zone, Jilin Province, is a high-tech manufacturing enterprise specializing in the research, development, production, and sales of fine chemical products. Its industry classification is Chemical Raw Materials and Chemical Products Manufacturing (C26), with a focus on pharmaceutical intermediates, electronic chemicals, and monomers for novel functional materials. The company is currently in a phase of concurrent large-scale mass production and downstream customer validation. Its core business includes high-purity N-Methyl-2-pyrrolidone (NMP), γ-Butyrolactone (GBL), lithium battery additive Vinylene Carbonate (VC), and customized fluorinated pharmaceutical intermediates, primarily serving manufacturers of new-energy power battery electrolytes, OLED display material enterprises, and CRO/CDMO pharmaceutical R&D institutions. The company possesses capabilities in the development and engineering implementation of continuous distillation coupled with catalytic dehydration processes for electronic-grade chemicals; it operates a 5,000-ton-per-year electronic-grade NMP purification facility and a 300-ton-per-year VC synthesis pilot line. It holds seven authorized patents, including the invention patent “Method for Preparing High-Purity NMP” (ZL201910823456.7); three of these invention patents remain valid. The company has obtained ISO 9001:2015 Quality Management System Certification (valid until September 28, 2025) and ISO 14001:2015 Environmental Management System Certification; it also holds the “Work Safety Production License” (Ji MK An Xu Zheng Zi [2021] No. 0017), the “National Industrial Product Production License” (XK13-014-00122), and the “Pollutant Discharge Permit” issued by the Jilin Provincial Department of Ecology and Environment (valid until February 2027). Representative achievements include: serving as a Tier-2 supplier to Contemporary Amperex Technology Co., Limited (CATL) for electronic-grade NMP support services continuously from 2022 to 2024; undertaking the key project “Green Synthesis Process Development for High-Stability VC for Lithium Batteries” under the Jilin Provincial Science and Technology Development Program in 2023, which passed acceptance in October 2024; and signing a small-batch supply agreement for OLED encapsulation material precursors with Hefei Xinsheng Optoelectronics Co., Ltd., a subsidiary of BOE Technology Group, in 2025. Publicly available information does not indicate overseas investment, export customs declarations, international certifications such as FDA/EMA/REACH, or AEO Advanced Certification status. All tendering activities, contracts, and media reports pertain exclusively to domestic operations, with customers concentrated in the East China, South China, and Northeast China regions; no publicly disclosed cross-border project deliveries or consortium collaborations exist.